

M2Bio Opens Bangkok Office and Appoints Managing Director

CAPE TOWN, WESTERN CAPE, SOUTH AFRICA, February 2, 2023 /EINPresswire.com/ -- Institute of Biomedical Research (OTC PINK: MRES) ("M2Bio Sciences" or the "Company"), a biotechnology company focused on alternative plant-based cannabinoids and mental health clinical research is pleased to share the following update:

M2Bio Sciences is pleased to announce the opening of corporate offices in Bangkok, Thailand. The operations are being headed up by the newly appointed Managing Director, Jade Sirisompan. Jade has an MSC in psychology and has been working in the mental health sector for the past two years. Jade also has extensive experience in the Muay Thai and fitness industry as a professional fighter and champion, personal trainer, gym manager and fight promoter. Jade was born and raised in England until the age of 14, then moved to Thailand.



Under the guidance of Jade's father, Muay Thai legend
Chinawut Sirisompan, famously known as Grandmaster Woody, she found a passion for the
Martial Arts industry, management, teaching, promotions, and more.


"My past experiences have helped me develop great resilience, social and emotional intelligence, cultural competency, and empathy for people from all walks of life, which have ultimately helped guide me in my profession of counseling psychology."

"The mental wellness sector is continuously evolving and with M2bio Sciences the future looks very bright. They have such impressive clinical evidence-based research and quality premium products, all with the purpose of optimizing health. From the revolutionary mycelium and hemp for packaging, psychedelics for treating mental health issues, and to the finest CBD infused organic honey, coffee, and olive oil for nutritional and peak cognitive functioning."

"M2bio also supports and is highly engaged in sport, fitness, and entertainment. In collaboration

with the EFC MMA Championship, the sport is used to educate and inspire the general public on positive health practices and provide athletes with sponsorship opportunities. The M2Bio vision is expansive and they understand the many areas in which health outcomes can be improved. As someone who is seriously passionate about health, psychology, and helping people improve their quality of life, together with my background in the combat sports industry I am very excited and truly honored to be a part of the m2bio team and to help M2Bio Sciences Thailand come to life." - Jade Sirisompan, Managing Director of M2Bio Sciences Thailand.

"We are truly excited and fortunate to have such a dedicated professional in our corner. Her positive energy is an inspiration for the current and next generation of athletes. The



M2Bio and EFC teams are very excited to be working with Jade. And remember, always be connecting the dots" - said Jeff Robinson, CEO of M2Bio Sciences.

About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES". Publicly traded company (OTC Pink:MRES)

Website: www.m2bio.co E-mail: info@m2bio.co

Find M2Bio™ on social media

Follow us on Facebook: <u>m2bio.sciences</u>
Follow us on Instagram: M2Bio Sciences
Follow us on LinkedIn: <u>M2Bio Sciences</u>, Inc.

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

Jeff Robinson M2Bio Sciences Food and Beverage (Pty) Ltd +27 72 333 2148 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/614126470 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.